Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

645 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia.
Klisovic RB, Blum W, Wei X, Liu S, Liu Z, Xie Z, Vukosavljevic T, Kefauver C, Huynh L, Pang J, Zwiebel JA, Devine S, Byrd JC, Grever MR, Chan K, Marcucci G. Klisovic RB, et al. Among authors: devine s. Clin Cancer Res. 2008 Jun 15;14(12):3889-95. doi: 10.1158/1078-0432.CCR-08-0109. Clin Cancer Res. 2008. PMID: 18559610 Free PMC article. Clinical Trial.
Pilot trial of interleukin-2 with granulocyte colony-stimulating factor for the mobilization of progenitor cells in advanced breast cancer patients undergoing high-dose chemotherapy: expansion of immune effectors within the stem-cell graft and post-stem-cell infusion.
Sosman JA, Stiff P, Moss SM, Sorokin P, Martone B, Bayer R, van Besien K, Devine S, Stock W, Peace D, Chen Y, Long C, Gustin D, Viana M, Hoffman R. Sosman JA, et al. Among authors: devine s. J Clin Oncol. 2001 Feb 1;19(3):634-44. doi: 10.1200/JCO.2001.19.3.634. J Clin Oncol. 2001. PMID: 11157013 Clinical Trial.
Primary amyloidosis patients with significant organ dysfunction tolerate autologous transplantation after conditioning with single-dose total body irradiation alone: a feasibility study.
Blum W, Khoury H, Lin HS, Vij R, Goodnough LT, Devine S, Dipersio J, Adkins D. Blum W, et al. Among authors: devine s. Biol Blood Marrow Transplant. 2003 Jun;9(6):397-404. doi: 10.1016/s1083-8791(03)00106-x. Biol Blood Marrow Transplant. 2003. PMID: 12813448 Free article.
Chimerism and clinical outcomes of 110 recipients of unrelated donor bone marrow transplants who underwent conditioning with low-dose, single-exposure total body irradiation and cyclophosphamide.
Girgis M, Hallemeier C, Blum W, Brown R, Lin HS, Khoury H, Goodnough LT, Vij R, Devine S, Wehde M, Postma S, Oza A, Dipersio J, Adkins D. Girgis M, et al. Among authors: devine s. Blood. 2005 Apr 15;105(8):3035-41. doi: 10.1182/blood-2003-07-2346. Epub 2004 May 4. Blood. 2005. PMID: 15126314 Free article.
Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies.
Rafiq S, Siadak A, Butchar JP, Cheney C, Lozanski G, Jacob NK, Lapalombella R, McGourty J, Moledor M, Lowe R, Setter B, Jones J, Flynn JM, Andritsos L, Devine S, Mo X, Jarjoura D, Tridandapani S, Algate P, Byrd JC, Muthusamy N. Rafiq S, et al. Among authors: devine s. MAbs. 2013 Sep-Oct;5(5):723-35. doi: 10.4161/mabs.25282. Epub 2013 Jun 7. MAbs. 2013. PMID: 23883821 Free PMC article.
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.
Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ, Ferenchak G, Dorrance AM, Paisie CA, Eiring AM, Ma Y, Mao HC, Zhang B, Wunderlich M, May PC, Sun C, Saddoughi SA, Bielawski J, Blum W, Klisovic RB, Solt JA, Byrd JC, Volinia S, Cortes J, Huettner CS, Koschmieder S, Holyoake TL, Devine S, Caligiuri MA, Croce CM, Garzon R, Ogretmen B, Arlinghaus RB, Chen CS, Bittman R, Hokland P, Roy DC, Milojkovic D, Apperley J, Goldman JM, Reid A, Mulloy JC, Bhatia R, Marcucci G, Perrotti D. Neviani P, et al. Among authors: devine s. J Clin Invest. 2013 Oct;123(10):4144-57. doi: 10.1172/JCI68951. Epub 2013 Sep 3. J Clin Invest. 2013. PMID: 23999433 Free PMC article.
The hematopoietic stem cell transplant comorbidity index can predict for 30-day readmission following autologous stem cell transplant for lymphoma and multiple myeloma.
Jaglowski SM, Ruppert AS, Hofmeister CC, Elder P, Blum W, Klisovic R, Vasu S, Penza S, Efebera YA, Benson DM Jr, Devine SM, Andritsos LA. Jaglowski SM, et al. Among authors: devine sm. Bone Marrow Transplant. 2014 Oct;49(10):1323-9. doi: 10.1038/bmt.2014.155. Epub 2014 Jul 28. Bone Marrow Transplant. 2014. PMID: 25068419 Free PMC article.
Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103).
Beumer JH, Owzar K, Lewis LD, Jiang C, Holleran JL, Christner SM, Blum W, Devine S, Kolitz JE, Linker C, Vij R, Alyea EP, Larson RA, Ratain MJ, Egorin MJ. Beumer JH, et al. Among authors: devine s. Cancer Chemother Pharmacol. 2014 Nov;74(5):927-38. doi: 10.1007/s00280-014-2571-0. Epub 2014 Aug 28. Cancer Chemother Pharmacol. 2014. PMID: 25163570 Free PMC article. Clinical Trial.
645 results